Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Effects of Rhodiola Rosea Supplementation on Anaerobic Performance and Blood Lactate in Trained Men

maanantai 9. marraskuuta 2026 päivittänyt: Yucel Makaraci, Karamanoğlu Mehmetbey University

Effects of Short-term Rhodiola Rosea Supplementation on Anaerobic Performance and Serial Post-exercise Blood Lactate Responses in Trained Men: A Randomized, Double-blind, Placebo-controlled Crossover Trial

This study aimed to investigate the effects of short-term Rhodiola rosea supplementation on anaerobic exercise performance and blood lactate responses during post-exercise recovery in trained male athletes.

The study used a randomized, double-blind, placebo-controlled crossover design involving 23 trained men. Each participant completed two experimental conditions: Rhodiola rosea supplementation and placebo, administered in a randomized order with a 5-day washout period between conditions.

During the Rhodiola rosea condition, participants received 1,500 mg per day for three consecutive days, followed by an additional 500 mg dose 30 minutes before exercise testing. The placebo condition followed an identical administration schedule without the active supplement.

Following each supplementation condition, participants performed a 30-second Wingate Anaerobic Test to assess anaerobic performance. Blood lactate concentrations were measured before exercise and at 3, 10, and 20 minutes after exercise.

The study was designed to determine whether short-term Rhodiola rosea supplementation influences maximal anaerobic performance and blood lactate concentrations during recovery from high-intensity exercise.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Rhodiola rosea is a plant-derived supplement containing bioactive compounds, including rosavins and salidroside, that have been investigated for their potential effects on physical performance, fatigue, and exercise-related physiological responses. Although previous research has examined the effects of Rhodiola rosea on different exercise modalities, evidence regarding its influence on anaerobic performance and serial blood lactate responses following a single bout of high-intensity exercise remains limited.

This study investigated whether short-term Rhodiola rosea supplementation affects performance during a 30-second Wingate Anaerobic Test (WAnT-30) and blood lactate concentrations during subsequent recovery.

The study employed a randomized, double-blind, placebo-controlled crossover design. Twenty-three trained male athletes completed both supplementation conditions in a randomized sequence. Participants received either Rhodiola rosea or placebo during the first experimental period and the alternate condition during the second period. A 5-day supplement-free washout interval separated the two supplementation periods.

The Rhodiola rosea supplementation protocol consisted of 1,500 mg daily for three consecutive days, administered in three separate 500 mg doses, followed by an additional 500 mg dose 30 minutes before the exercise test. The placebo consisted of an identically flavored non-caloric beverage without active supplementation. Both preparations were administered under standardized conditions to maintain blinding.

Following each supplementation period, participants completed a standardized warm-up and performed a maximal 30-second Wingate test using a cycle ergometer. Anaerobic performance variables included peak power, relative peak power, mean power, total work, cadence at peak power, and rate of fatigue.

Capillary blood lactate concentrations were assessed at rest and at 3, 10, and 20 minutes following the Wingate test. Participants remained seated throughout the post-exercise recovery period.

Dietary intake, physical activity, caffeine consumption, and testing conditions were standardized as far as possible to minimize potential confounding effects.

The study was designed to evaluate the effects of short-term Rhodiola rosea supplementation on maximal anaerobic performance and post-exercise blood lactate responses compared with placebo.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

23

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Karaman
      • Karaman, Karaman, Turkki (Türkiye), 70200
        • Faculty of Sports Sciences Exercise Physiology Laboratory

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 24 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Uros

Kuvaus

Inclusion Criteria:

  • Healthy male athletes aged 18 years or older.
  • Regular participation in sport-specific training at least three times per week.
  • Active participation in organized competitive sports.
  • Engagement in structured training aimed at improving athletic performance.
  • Regular participation in lower-body resistance training as part of habitual training programs.
  • Previous experience with submaximal exercise testing on a cycle ergometer.
  • No musculoskeletal injuries or medical conditions that could affect exercise performance.
  • Maintenance of regular training during the month preceding the study.
  • Voluntary participation and provision of written informed consent.

Exclusion Criteria:

  • Previous use of Rhodiola rosea supplementation.
  • Use of any ergogenic supplements within one week before the beginning of the study or during the experimental period.
  • History of lower-limb surgery within the previous 12 months.
  • Presence of musculoskeletal injuries or medical conditions that could interfere with exercise performance.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Rhodiola rosea Followed by Placebo

Subjects assigned to this sequence received Rhodiola rosea supplementation during the first experimental period, followed by placebo during the second period. Rhodiola rosea was administered at 1,500 mg/day for three consecutive days, with an additional 500 mg dose 30 minutes before the Wingate test. A 5-day supplement-free washout period separated the two experimental periods. Twelve subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

Kokeellinen: Placebo Followed by Rhodiola rosea

Subjects assigned to this sequence received placebo during the first experimental period, followed by Rhodiola rosea supplementation during the second period. The placebo followed the same administration schedule as the active supplementation condition but contained no Rhodiola rosea extract. A 5-day supplement-free washout period separated the two experimental periods. Eleven subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Peak Power During the 30-Second Wingate Anaerobic Test
Aikaikkuna: During the 30-second Wingate test at the end of each 4-day supplementation period

Peak power (W) was measured during the 30-second Wingate Anaerobic Test using a cycle ergometer (Lode Excalibur Sport). The highest power output achieved during the test was recorded and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Post-Exercise Blood Lactate Concentration
Aikaikkuna: At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Capillary blood lactate concentration (mmol/L) was measured using a portable lactate analyzer (Lactate Scout Sport) at rest and at 3, 10, and 20 minutes after the 30-second Wingate Anaerobic Test. Blood lactate concentrations were compared between the Rhodiola rosea and placebo conditions at each measurement time point.

At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Relative Peak Power During the 30-Second Wingate Anaerobic Test
Aikaikkuna: During the 30-second Wingate test at the end of each 4-day supplementation period

Relative peak power (W/kg) was calculated by normalizing the highest power output achieved during the 30-second Wingate Anaerobic Test to the subject's body mass. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Mean Power During the 30-Second Wingate Anaerobic Test
Aikaikkuna: During the 30-second Wingate test at the end of each 4-day supplementation period

Mean power (W) was determined as the average mechanical power output generated throughout the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Total Work During the 30-Second Wingate Anaerobic Test
Aikaikkuna: During the 30-second Wingate test at the end of each 4-day supplementation period

Total work (kJ) was determined as the cumulative mechanical work performed throughout the 30-second Wingate Anaerobic Test. Values were derived from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Cadence at Peak Power During the 30-Second Wingate Anaerobic Test
Aikaikkuna: During the 30-second Wingate test at the end of each 4-day supplementation period

Cadence at peak power (rpm) was recorded as the pedaling rate corresponding to the highest power output achieved during the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Rate of Fatigue During the 30-Second Wingate Anaerobic Test
Aikaikkuna: During the 30-second Wingate test at the end of each 4-day supplementation period

Rate of fatigue (%) was obtained from the cycle ergometer software as an indicator of the relative decline in power output during the 30-second Wingate Anaerobic Test. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Yücel Makaracı, PhD, Karamanoğlu Mehmetbey University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 1. toukokuuta 2026

Ensisijainen valmistuminen (Todellinen)

Perjantai 15. toukokuuta 2026

Opintojen valmistuminen (Todellinen)

Perjantai 15. toukokuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 9. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 16. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 16. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • KMU-09-2025/153
  • 15-YL-25 (Muu apuraha/rahoitusnumero: Karamanoğlu Mehmetbey University (KMU) Scientific 645 Research Projects (BAP) Unit)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

De-identified individual participant data may be made available from the corresponding author upon reasonable request. Data will not be publicly accessible due to participant privacy considerations. Each request will be evaluated individually based on its scientific purpose, ethical considerations, and applicable data protection requirements. Data sharing will be subject to appropriate safeguards to protect participant confidentiality.

IPD-jaon aikakehys

Following publication of the study results, upon reasonable request.

IPD-jaon käyttöoikeuskriteerit

Qualified researchers may request access to de-identified individual participant data by contacting the corresponding author. Each request will be evaluated individually based on its scientific purpose, methodological justification, and compliance with applicable ethical and data protection requirements. Data may be shared upon reasonable request, provided that participant confidentiality and privacy are adequately protected.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa